Germinario RJ, Desantis T, Wainberg MA; National Conference on Human Retroviruses and Related Infections.
Program Abstr Second Natl Conf Hum Retrovir Relat Infect Natl Conf Hum Retrovir Relat Infect 2nd 1995 Wash DC. 1995 Jan 29-Feb 2; 149.
Lady Davis Institute, Montreal, Quebec, Canada.
The effects of IGF-1 and I on HIV replication were studied in cord blood mononuclear cell (CBMC) and a chronically infected U937 cell line. Media levels of reverse transcriptase (RT) and p24 antigen were used to monitor HIV replication. HIV replication was inhibited by IGF-1 and I in de novo infected (i.e. first exposure to virus, TCID 2000) CBMC (4-7 days post infection and hormone exposure) and in chronically infected U937 cells (1-2 days post hormone exposure). In CBMC, the 50% effective dose for IGF-1 was found to be in the physiologic range (2.5-4.5 nM) while that for I was considerably higher (1.1-3.3 micromolar). In chronically infected U937 cells, HIV replication was inhibited 32% by 0.7 micromolar I and 93% by 13 nM IGF-1. IGF-1 and I at the maximal concentrations employed exhibited no toxicity on the cells used in these studies. Further, neither IGF-1 nor I showed any inhibitory activity on purified RT in vitro. Epidermal growth factor at concentrations known to be mitogenic (i.e. 16 nM) had no inhibitory effect on HIV replication demonstrating the specificity of the IGF-1 effect. These results indicate that IGF-1 at physiological concentrations can have significant inhibitory effects on HIV replication. This may prove to be of therapeutic value in AIDS patients.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- HIV Infections
- HIV Seropositivity
- Humans
- In Vitro
- Insulin
- Insulin-Like Growth Factor I
- Insulin-Like Growth Factor II
- RNA-Directed DNA Polymerase
- Receptor, Insulin
Other ID:
UI: 102213488
From Meeting Abstracts